Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina
The introduction of upadacitinib in MS-AD treatment was associated with modest savings for the social security and private payer budget in Argentina.
Authors
- Federico Rodríguez Cairoli (ORCID: https://orcid.org/0000-0002-3029-4439)
- Andrés Pichon-Riviere
- Carlos Rojas‐Roque (ORCID: https://orcid.org/0000-0002-1474-1550)
- Natalia Espínola (ORCID: https://orcid.org/0000-0001-5511-3561)
- Diego Kanevsky
- Paula Carolina Luna (ORCID: https://orcid.org/0000-0002-8002-4234)
- Valeria Migliazza
Institutions
- Instituto de Efectividad Clínica y Sanitaria (AR)
- Hospital Alemán (AR)
- University of York (GB)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1080/14737167.2024.2394124
- Citations
- 2
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- AbbVie